IGF2 and meningioma: Inhibition of the miR-483/IGF-2 pathway with miR-483 oligonucleotide inhibitor, anti-IGF-2 neutralizing antibodies, and IGF1R small molecule tyrosine kinase inhibitors caused rapid loss of viability of cultured meningioma tumor-derived cells.